ZOLINZA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zolinza, and when can generic versions of Zolinza launch?
Zolinza is a drug marketed by Msd Sub Merck and is included in one NDA. There are five patents protecting this drug.
This drug has one hundred and thirty-one patent family members in thirty-five countries.
The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.
DrugPatentWatch® Generic Entry Outlook for Zolinza
Zolinza was eligible for patent challenges on October 6, 2010.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 11, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ZOLINZA
International Patents: | 131 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 136 |
Clinical Trials: | 161 |
Patent Applications: | 4,132 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZOLINZA |
What excipients (inactive ingredients) are in ZOLINZA? | ZOLINZA excipients list |
DailyMed Link: | ZOLINZA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZOLINZA
Generic Entry Date for ZOLINZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ZOLINZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oregon Health and Science University | Phase 1 |
OHSU Knight Cancer Institute | Phase 1 |
Prospect Creek Foundation | Phase 1 |
Pharmacology for ZOLINZA
Drug Class | Histone Deacetylase Inhibitor |
Mechanism of Action | Histone Deacetylase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ZOLINZA
US Patents and Regulatory Information for ZOLINZA
ZOLINZA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZOLINZA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZOLINZA
Methods of treating cancer with HDAC inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Polymorphs of suberoylanilide hydroxamic acid
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Polymorphs of suberoylanilide hydroxamic acid
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOLINZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZOLINZA
See the table below for patents covering ZOLINZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2671976 | PROCEDES D'INDUCTION DE DIFFERENCIATION TERMINALE (METHODS OF INDUCING TERMINAL DIFFERENTIATION) | ⤷ Try a Trial |
European Patent Office | 2229941 | Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production (Formulations of suberoylanilide hydroxamic acid and methods for producing same) | ⤷ Try a Trial |
Dominican Republic | P2006000113 | FORMULACIONES DE ÁCIDO HIDROXÁMICO SUBEROILANILIDA Y PROCEDIMIEMTOS PARA LA PRODUCCIÓN DE LAS MISMAS | ⤷ Try a Trial |
New Zealand | 594669 | Oral composition of Vorinostat | ⤷ Try a Trial |
China | 1720034 | Methods of inducing terminal differentiation | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |